Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, SE5 8AZ, UK.
Institute of Pharmaceutical Sciences, King's College London, London, UK.
BMC Psychiatry. 2022 Apr 20;22(1):277. doi: 10.1186/s12888-022-03940-0.
The objective of the study is to explore the long-term effectiveness and tolerability of metoclopramide in the treatment of CIH.
This study is a retrospective, observational cohort study of patients prescribed metoclopramide for CIH at the South London & Maudsley (SLaM) NHS Foundation Trust.
Of the 96 patients identified, 14 patients were eligible for inclusion in our study. Five patients continued treatment with a mean duration of 27 months (SD = 17.8), and one patient continued until transfer with a duration of 3 months. Eight patients discontinued treatment after a mean duration of 8 months.
Metoclopramide may be an effective and tolerated drug in CIH, but more data is required to establish its place in the pharmacotherapy of this condition.
本研究旨在探讨甲氧氯普胺治疗 CIH 的长期疗效和耐受性。
本研究为回顾性、观察性队列研究，纳入在南伦敦和莫兹利 NHS 基金会信托基金（South London & Maudsley (SLaM) NHS Foundation Trust）接受甲氧氯普胺治疗 CIH 的患者。
在确定的 96 名患者中，有 14 名患者符合纳入本研究的条件。5 名患者继续接受治疗，平均持续时间为 27 个月（SD=17.8），1 名患者持续治疗 3 个月后转院。8 名患者平均停药 8 个月后停药。
甲氧氯普胺可能是 CIH 的一种有效且耐受良好的药物，但需要更多的数据来确定其在该疾病药物治疗中的地位。
